Singapore markets open in 5 hours 41 minutes

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.4650-0.1050 (-2.30%)
As of 03:19PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close4.5700
Bid4.4800 x 1200
Ask4.4900 x 2900
Day's range4.4600 - 4.8399
52-week range4.4100 - 10.4100
Avg. volume6,170,985
Market cap1.106B
Beta (5Y monthly)0.09
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Motley Fool

    Why Iovance Biotherapeutics Stock Rocketed 13% Higher Today

    The approval process for the biotech's most advanced pipeline drug program is going quite well, it seems.

  • Zacks

    Iovance (IOVA) Up Despite FDA's Delayed Decision on Melanoma Drug

    Iovance (IOVA) rises despite the FDA's postponement of the decision date regarding the regulatory filing for its lead candidate, lifileucel, to treat advanced melanoma due to resource constraints.

  • Motley Fool

    Why Shares of Iovance Biotherapeutics Dropped Thursday

    Shares of Iovance Biotherapeutics (NASDAQ: IOVA) fell more than 13% on Thursday. The biotech company, which specializes in using tumor-infiltrating lymphocyte (TIL) therapies to fight cancer, has seen its shares drop by more than 25% so far this year, hitting a 52-week low of $4.41 on Thursday. Lifileucel is also being looked at to treat melanoma, non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).